Boston Scientific’s Vercise Deep Brain Stimulation (DBS) System has received CE Mark approval for the treatment of intractable primary and secondary dystonia, a neurological movement disorder characterized by involuntary muscle contractions, the company reported Tuesday.

Dystonia affects more than 500,000 people across Europe. It is the third most common movement disorder after Parkinson's disease and essential tremor. Symptoms include involuntary muscle contractions, which can be painful and debilitating.  Boston Scientific says the Vercise DBS System is the first system designed to selectively stimulate targeted areas of the brain in order to customize therapy and manage symptoms of Parkinson's disease.  This system now offers treatment for patients with dystonia.  

"Historically, treatment of secondary dystonia has been challenging and efficacy was typically incomplete and partially limited by side effects.  The Vercise DBS system represents an advancement in dystonia care by providing more flexible and unique programming options for targeted deep brain stimulation tailored to each individual," said Prof. Dr. Andrea Kühn.

For more information, go to: